| Business Summary | | C.
R.
Bard,
Inc.
is
engaged
in
the
design,
manufacture,
packaging,
distribution
and
sale
of
medical,
surgical,
diagnostic
and
patient-care
devices.
The
Company
markets
its
products
worldwide
to
hospitals,
individual
healthcare
professionals,
extended-care
facilities
and
alternate-site
facilities.
Hospitals,
physicians
and
nursing
homes
purchase
approximately
90%
of
the
Company's
products,
most
of
which
are
used
once
and
discarded.
Three
of
Bard's
four
major
product
group
categories
are
vascular
diagnosis
and
intervention,
urological
diagnosis
and
intervention
and
oncological
diagnosis
and
intervention.
In
addition,
the
Company
maintains
and
grows
its
fourth
major
product
group,
surgical
specialties,
and
also
has
a
product
group
of
other
ongoing
products. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | BCR
develops,
manufactures
and
markets
health
care
products,
including
vascular,
urological
and
oncological
diagnosis
and
intervention
products,
sold
worldwide
to
hospitals,
health
care
professionals,
and
extended
care
and
alternate
site
facilities.
For
the
six
months
ended
6/01,
sales
rose
7%
to
$580.7
million.
Net
income
rose
6%
to
$68.2
million.
Results
reflect
increased
sales
of
surgery
products
partially
offset
by
the
absence
of
a
$15.4
million
gain
from
the
sale
of
businesses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| William Longfield, 26 Chairman,
CEO | $2.2M | $929K | Charles Slacik, 46 CFO,
Sr. VP | 664K | -- | Todd Schermerhorn, 40 VP
and Treasurer | -- | -- | Charles Grom, 53 VP
and Controller | -- | -- | Nadia Adler, 56 VP,
Gen. Counsel and Sec. | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|